Pharmacologically acceptable solvent vehicles

Details Pharmacologically acceptable solvent vehicles Pharmacologically acceptable solvent vehicles

2006-12-26

2006-12-26

Levy, Neil S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S405000, C424S406000, C424S450000, C514S937000, C514S938000, C514S970000, C514S974000

Reexamination Certificate

active

07153838

ABSTRACT:
An antifungal composition suitable for parenteral administration to a mammal includes an amount of pimaricin or an antifungal derivative thereof that is effective to inhibit the growth of a fungal infection in a mammal; a pharmaceutically acceptable dipolar aprotic solvent; and a pharmaceutically acceptable aqueous secondary solvent. The composition can be used in methods of preventing or treating a systemic fungal infection in a mammal. The composition can be prepared by dissolving pimaricin or an antifungal derivative thereof in the pharmaceutically acceptable dipolar aprotic solvent; adding to the solution a pharmaceutically acceptable aqueous secondary solvent; and in a preferred method, by subsequently lypohilizing the composition, whereby a dry, shelf-stable composition is produced. This dry composition can be reconstituted into an aqueous solution suitable for parenteral administration.

REFERENCES:
patent: 3343968 (1967-09-01), Huhtanen
patent: 3892850 (1975-07-01), Struyk et al.
patent: 4148891 (1979-04-01), Smink
patent: 4536494 (1985-08-01), Carter
patent: 4600706 (1986-07-01), Carter
patent: 4766046 (1988-08-01), Abra et al.
patent: 4883785 (1989-11-01), Chow et al.
patent: 4950477 (1990-08-01), Schmitt et al.
patent: 5277914 (1994-01-01), Szoka, Jr.
patent: 5430057 (1995-07-01), Andersson et al.
patent: 5552151 (1996-09-01), Noordam et al.
patent: 5559148 (1996-09-01), Andersson et al.
patent: 5651991 (1997-07-01), Sugiyama et al.
patent: 5821233 (1998-10-01), Van Rijn et al.
patent: 5877205 (1999-03-01), Andersson
patent: 6045815 (2000-04-01), Andersson et al.
patent: 6107333 (2000-08-01), Andersson
patent: 6291500 (2001-09-01), Ponikau
patent: 6369036 (2002-04-01), Van Rijn et al.
patent: 6406713 (2002-06-01), Janoff et al.
patent: 0 664 130 (1995-07-01), None
patent: 1457327 (1976-12-01), None
patent: 2 106 498 (1983-04-01), None
patent: 2 116 425 (1983-09-01), None
patent: WO 93/07884 (1993-04-01), None
patent: 96/29998 (1996-10-01), None
patent: WO 96/29998 (1996-10-01), None
Yalkowsky et al., “Solubilization of Drugs by Cosolvents,” Techniques of Solubilization of Drugs, pp. 91-134, Marcel Dekker Inc., NY (1981).
Spiegel et al., “Use of Nonaqueous Solvents in Parenteral Products,” Journal of Pharmaceutical Sciences, vol. 52, No. 10, , pp. 917-927 (Oct. 1963).
Drug Facts and Comparisons, Wolters Kluwer Co., St. Louis, MO, , Intravenous Nutritional Therapy, p. 138 (1977 edition).
Drug Information for the Health Care Professional: USPDI, p. 1705, (1989 edition).
Korteweg et al., “Some pharmacological properties of Pimaricin and possible clinical application of this antifungal antibiotic,”Iind int. Symp. Chemotherapy, 261-272, 1963.
Raab, “:Natamycin (Pimaricin) its properties and Possibilities in medicine,” 1-134, Georg Thieme Publishers Stuttgart, 1972.

Affiliated with

Also associated with

Rating

Pharmacologically acceptable solvent vehicles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmacologically acceptable solvent vehicles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmacologically acceptable solvent vehicles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3699024